These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28066877)

  • 1. Central noradrenaline transporter availability in highly obese, non-depressed individuals.
    Hesse S; Becker GA; Rullmann M; Bresch A; Luthardt J; Hankir MK; Zientek F; Reißig G; Patt M; Arelin K; Lobsien D; Müller U; Baldofski S; Meyer PM; Blüher M; Fasshauer M; Fenske WK; Stumvoll M; Hilbert A; Ding YS; Sabri O
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):1056-1064. PubMed ID: 28066877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noradrenaline transporter availability on [
    Vettermann FJ; Rullmann M; Becker GA; Luthardt J; Zientek F; Patt M; Meyer PM; McLeod A; Brendel M; Blüher M; Stumvoll M; Hilbert A; Ding YS; Sabri O; Hesse S
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1618-1625. PubMed ID: 29627935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[(11)C]O-methylreboxetine.
    Li CS; Potenza MN; Lee DE; Planeta B; Gallezot JD; Labaree D; Henry S; Nabulsi N; Sinha R; Ding YS; Carson RE; Neumeister A
    Neuroimage; 2014 Feb; 86():306-10. PubMed ID: 24121204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central serotonin transporter availability in highly obese individuals compared with non-obese controls: A [(11)C] DASB positron emission tomography study.
    Hesse S; Rullmann M; Luthardt J; Winter K; Hankir MK; Becker GA; Zientek F; Reissig G; Regenthal R; Drabe M; Schinke C; Bresch A; Arelin K; Lobsien D; Patt M; Meyer PM; Fasshauer M; Fenske WK; Blüher M; Stumvoll M; Sabri O
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1096-104. PubMed ID: 26577939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emotional eating and in vivo norepinephrine transporter availability in obesity: A [
    Bresch A; Rullmann M; Luthardt J; Becker GA; Reissig G; Patt M; Ding YS; Hilbert A; Sabri O; Hesse S
    Int J Eat Disord; 2017 Feb; 50(2):152-156. PubMed ID: 27611116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hunger and disinhibition but not cognitive restraint are associated with central norepinephrine transporter availability.
    Bresch A; Rullmann M; Luthardt J; Becker GA; Patt M; Ding YS; Hilbert A; Sabri O; Hesse S
    Appetite; 2017 Oct; 117():270-274. PubMed ID: 28647385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between in vivo central noradrenaline transporter availability and trait impulsivity.
    Hesse S; Müller U; Rullmann M; Luthardt J; Bresch A; Becker GA; Zientek F; Patt M; Meyer PM; Blüher M; Strauß M; Fenske W; Hankir M; Ding YS; Hilbert A; Sabri O
    Psychiatry Res Neuroimaging; 2017 Sep; 267():9-14. PubMed ID: 28675825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging human brown adipose tissue under room temperature conditions with (11)C-MRB, a selective norepinephrine transporter PET ligand.
    Hwang JJ; Yeckel CW; Gallezot JD; Aguiar RB; Ersahin D; Gao H; Kapinos M; Nabulsi N; Huang Y; Cheng D; Carson RE; Sherwin R; Ding YS
    Metabolism; 2015 Jun; 64(6):747-55. PubMed ID: 25798999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography.
    Vanicek T; Spies M; Rami-Mark C; Savli M; Höflich A; Kranz GS; Hahn A; Kutzelnigg A; Traub-Weidinger T; Mitterhauser M; Wadsak W; Hacker M; Volkow ND; Kasper S; Lanzenberger R
    JAMA Psychiatry; 2014 Dec; 71(12):1340-1349. PubMed ID: 25338091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships of in vivo brain norepinephrine transporter and age, BMI, and gender.
    Koohsari S; Sadabad FE; Pittman B; Gallezot JD; Carson RE; van Dyck CH; Li CR; Potenza MN; Matuskey D
    Synapse; 2023 Sep; 77(5):e22279. PubMed ID: 37382240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Norepinephrine transporter availability in brown fat is reduced in obesity: a human PET study with [
    Sanchez-Rangel E; Gallezot JD; Yeckel CW; Lam W; Belfort-DeAguiar R; Chen MK; Carson RE; Sherwin R; Hwang JJ
    Int J Obes (Lond); 2020 Apr; 44(4):964-967. PubMed ID: 31636373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes of central noradrenaline transporter availability in immunotherapy-naïve multiple sclerosis patients.
    Schmidt E; Schinke C; Rullmann M; Luthardt J; Becker GA; Haars S; Stoppe M; Lobsien D; Hoffmann KT; Sabri O; Hesse S; Then Bergh F
    Sci Rep; 2020 Sep; 10(1):14651. PubMed ID: 32887904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of norepinephrine transporter gene variants on NET binding in ADHD and healthy controls investigated by PET.
    Sigurdardottir HL; Kranz GS; Rami-Mark C; James GM; Vanicek T; Gryglewski G; Kautzky A; Hienert M; Traub-Weidinger T; Mitterhauser M; Wadsak W; Hacker M; Rujescu D; Kasper S; Lanzenberger R
    Hum Brain Mapp; 2016 Mar; 37(3):884-95. PubMed ID: 26678348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)-[(11)C]O-methylreboxetine and HRRT.
    Ding YS; Singhal T; Planeta-Wilson B; Gallezot JD; Nabulsi N; Labaree D; Ropchan J; Henry S; Williams W; Carson RE; Neumeister A; Malison RT
    Synapse; 2010 Jan; 64(1):30-8. PubMed ID: 19728366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adult attention-deficit/hyperactivity disorder is associated with reduced norepinephrine transporter availability in right attention networks: a (S,S)-O-[
    Ulke C; Rullmann M; Huang J; Luthardt J; Becker GA; Patt M; Meyer PM; Tiepolt S; Hesse S; Sabri O; Strauß M
    Transl Psychiatry; 2019 Nov; 9(1):301. PubMed ID: 31732713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET imaging of noradrenaline transporters in Parkinson's disease: focus on scan time.
    Brumberg J; Tran-Gia J; Lapa C; Isaias IU; Samnick S
    Ann Nucl Med; 2019 Feb; 33(2):69-77. PubMed ID: 30293197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noradrenergic Deficits in Parkinson Disease Imaged with
    Nahimi A; Sommerauer M; Kinnerup MB; Østergaard K; Winterdahl M; Jacobsen J; Schacht A; Johnsen B; Damholdt MF; Borghammer P; Gjedde A
    J Nucl Med; 2018 Apr; 59(4):659-664. PubMed ID: 28848039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Norepinephrine Transporter in Major Depressive Disorder: A PET Study.
    Moriguchi S; Yamada M; Takano H; Nagashima T; Takahata K; Yokokawa K; Ito T; Ishii T; Kimura Y; Zhang MR; Mimura M; Suhara T
    Am J Psychiatry; 2017 Jan; 174(1):36-41. PubMed ID: 27631962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress.
    Logan J; Wang GJ; Telang F; Fowler JS; Alexoff D; Zabroski J; Jayne M; Hubbard B; King P; Carter P; Shea C; Xu Y; Muench L; Schlyer D; Learned-Coughlin S; Cosson V; Volkow ND; Ding YS
    Nucl Med Biol; 2007 Aug; 34(6):667-79. PubMed ID: 17707807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effortful control as a dimension of temperament is negatively associated with prefrontal serotonin transporter availability in obese and non-obese individuals.
    Zientek F; Winter K; Müller A; Rullmann M; Luthardt J; Becker GA; Bresch A; Patt M; Sabri O; Hilbert A; Hesse S
    Eur J Neurosci; 2016 Oct; 44(7):2460-2466. PubMed ID: 27519298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.